Delving into the Latest Updates on Suzhou Erye Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Infectious Diseases

Otorhinolaryngologic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PBPs x β-lactamase	1
PBPs(Bacterial penicillin-binding protein)	1

This phase 1 study was designed to evaluate the safety and tolerability of SZEY-2108 in single and multiple intravenous infusions, the pharmacokinetic profile of SZEY-2108 after single and multiple intravenous infusions, and the effect of exposure to SZEY-2108 after a single intravenous infusion on QT/QTc interval. Metabolites in each biological matrix (blood, urine, feces) and excretion characteristics (feces) after SZEY-2108 were analyzed.

Start Date07 Sep 2023

Sponsor / Collaborator

Suzhou Erye Pharmaceutical Co., Ltd.

CTR20232519 / TerminatedPhase 1

评价注射用SZEY-2108在中国健康成年受试者中随机、双盲、安慰剂对照、单剂和多剂递增静脉输注给药的安全性、耐受性及药代动力学特征的I期临床研究

[Translation] A Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of SZEY-2108 for injection in healthy Chinese adult subjects using a randomized, double-blind, placebo-controlled, single-dose and multiple-dose ascending intravenous infusion

主要目的：评估注射用SZEY-2108在健康受试者中单剂和多剂静脉输注的安全性和耐受性。次要目的： 1）评估注射用SZEY-2108在健康受试者中单剂和多剂静脉输注的药代动力学特征。 2）评估健康受试者单剂静脉输注注射用SZEY-2108后的暴露量对其QT/QTc间期的影响。探索性目的：分析健康受试者注射SZEY-2108后各生物基质（血、尿、粪便）中的代谢产物和排泄特征（粪便）。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple intravenous infusions of SZEY-2108 for injection in healthy subjects. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of single and multiple intravenous infusions of SZEY-2108 for injection in healthy subjects. 2) To evaluate the effect of exposure after a single intravenous infusion of SZEY-2108 for injection on the QT/QTc interval in healthy subjects. Exploratory objectives: To analyze the metabolites and excretion characteristics (feces) in various biological matrices (blood, urine, feces) after injection of SZEY-2108 in healthy subjects.

Start Date05 Sep 2023

Sponsor / Collaborator

Suzhou Erye Pharmaceutical Co., Ltd.

CTR20220512 / CompletedNot Applicable

利丙双卡因乳膏随机、开放、两制剂、两周期、自身交叉、空腹给药健康人体生物等效性试验

[Translation] A randomized, open, two-formulation, two-period, self-crossover, fasting-administered bioequivalence study of leprocaine cream in healthy volunteers

主要目的：以苏州二叶制药有限公司提供的利丙双卡因乳膏（包装规格：30g/支）为受试制剂，以AstraZeneca AB（阿斯利康）的利丙双卡因乳膏(商品名：恩纳/EMLA，包装规格：30g/支)为参比制剂，评估受试制剂和参比制剂在空腹状态下给药时的生物等效性。次要目的：观察利丙双卡因乳膏受试制剂和参比制剂在健康人体中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test and reference preparations when the test and reference preparations were administered in the fasting state, using the test and reference preparations of Leprocaine Cream (packaging specification: 30g/tube) provided by Suzhou Erye Pharmaceutical Co., Ltd. as the test preparation and the Leprocaine Cream (trade name: EMLA, packaging specification: 30g/tube) of AstraZeneca AB as the reference preparation. Secondary objective: To observe the safety of the test and reference preparations of Leprocaine Cream in healthy humans.

Start Date06 Apr 2022

Sponsor / Collaborator

Suzhou Erye Pharmaceutical Co., Ltd.

100 Clinical Results associated with Suzhou Erye Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Erye Pharmaceutical Co., Ltd.

Login to view more data

3

Literatures (Medical) associated with Suzhou Erye Pharmaceutical Co., Ltd.

Dangdai Huagong Yanjiiu

Discussion on Application of Bioengineering Technology in Pharmaceutical Industry

Author: Shen Hao

The development of China's scientific and technol. capabilities has provided power for bioengineering, especially biopharmaceuticals, which need to be built on the basis of scientific and technol. foundation and medical development.It can be said that advanced science and technol. is the foundation of bioengineering.Biopharmaceutics is a process of using different equipment to transform plants under the guidance of biol.In order to improve the production level and save the production cost of drugs, this paper makes a discussion on the content of bioengineering in pharmacy, analyze the main contradictions in the pharmaceutical process in China, and thus propose different paths to solve the problems, providing reference opinions for the development of subsequent projects.

Scientific ReportsQ3 · CROSS-FIELD

By-Products of Heparin Production Provide a Diverse Source of Heparin-like and Heparan Sulfate Glycosaminoglycans

Q3 · CROSS-FIELD

ArticleOA

Author: Yates, Edwin A ; Hogwood, John ; Taylor, Sarah L ; Guo, Wei ; Turnbull, Jeremy E

AbstractGlobal production of pharmaceutical heparin (Hp) is increasing, and the production process from raw mucosal material results in large amounts of waste by-products. These contain lower sulfated Hp-like and heparan sulfate (HS), as well as other glycosaminoglycans, which are bioactive entities with pharmaceutical potential. Here we describe the first purification, structural and functional characterisation of Hp-like and HS polysaccharides from the four major by-product fractions of standard heparin production. Analysis of the by-products by disaccharide composition analysis and NMR demonstrated a range of structural characteristics which differentiate them from Hp (particularly reduced sulfation and sulfated disaccharide content), and that they are each distinct. Functional properties of the purified by-products varied, each displaying distinct anticoagulant profiles in different assays, and all exhibiting significantly lower global and specific inhibition of the coagulation pathway than Hp. The by-products retained the ability to promote cell proliferation via fibroblast growth factor receptor signalling, with only minor differences between them. These collective analyses indicate that they represent an untapped and economical source of structurally-diverse Hp-like and HS polysaccharides with the potential for enhancing future structure-activity studies and uncovering new biomedical applications of these important natural products.

Zhongguo Yaofang

Content determination of omeprazole sodium by rp-hplc

Author: Sun, Xiao-chen ; Zhong, Mei ; Shi, Ting-ting

A method for the content determination of omeprazole Na was presented.RP-HPLC was used.Amethyst C8 column was used with mobile phase consisted of 0.01 mol/L Na₂HPO₄ solution (pH adjusted to 7.6 with H₃PO₄)-acetonitrile (75:30, V/V) at the flow rate of 1.0 mL/min.The detection wavelength was 302 nm, and column temperature was 30°C.The sample size was 20 μL.The linear range of omeprazole Na was 8.7-43.4 μg/mL (r=0.999 9)with an average recovery of 100.65% (RSD=0.60%, n=9).RSDs of precision, stability, and reproducibility tests were all lower than 0.38%.The method is simple, rapid, accurate, and specific, and it is suitable for the content determination of omeprazole sodium.

100 Deals associated with Suzhou Erye Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Erye Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Approved

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Penicillin G Benzathine ( PBPs )	Infectious Diseases More	Approved
Amoxicillin/Clavulanate Potassium ( PBPs x β-lactamase )	Suppurative tonsillitis More	Phase 2
SZEY-2108	Carbapenem Resistant Bacterial Infection More	Discontinued
EY-1936	-	Pending